Breast cancer drug safety study ends early after enrolling just 4 patients
NCT ID NCT04967248
Summary
This study aimed to monitor the real-world safety of the drug alpelisib, combined with fulvestrant, in adults with a specific type of advanced breast cancer that had worsened after prior hormone therapy. It planned to track side effects like high blood sugar and jaw bone problems in patients receiving this treatment as part of their normal care. The study was terminated early because only four patients were enrolled, so no meaningful analysis was possible.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER WITH A PIK3CA MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.